ARGENX SE's ticker is ARGX and the CUSIP is 04016X101. A total of 135 filers reported holding ARGENX SE in Q1 2019. The put-call ratio across all filers is 3.30 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $1,195,000 | -88.4% | 4,064 | -89.6% | 0.03% | -92.3% |
| Q3 2020 | $10,282,000 | -44.1% | 39,168 | -52.1% | 0.35% | -47.5% |
| Q2 2020 | $18,402,000 | +27.8% | 81,704 | -25.3% | 0.66% | -14.3% |
| Q1 2020 | $14,403,000 | -40.2% | 109,338 | -27.2% | 0.78% | -30.0% |
| Q4 2019 | $24,102,000 | +39.4% | 150,148 | -1.1% | 1.11% | +16.5% |
| Q3 2019 | $17,296,000 | -15.2% | 151,770 | +5.3% | 0.95% | -5.6% |
| Q2 2019 | $20,403,000 | +12.4% | 144,106 | -0.9% | 1.01% | +3.4% |
| Q1 2019 | $18,150,000 | +3.8% | 145,386 | -20.1% | 0.98% | -21.3% |
| Q4 2018 | $17,489,000 | +27.1% | 182,040 | +0.4% | 1.24% | +66.1% |
| Q3 2018 | $13,756,000 | +74.0% | 181,379 | +90.1% | 0.75% | +56.7% |
| Q2 2018 | $7,906,000 | +108.7% | 95,419 | +102.6% | 0.48% | +73.7% |
| Q1 2018 | $3,789,000 | -28.1% | 47,100 | -43.5% | 0.27% | -33.8% |
| Q4 2017 | $5,267,000 | – | 83,418 | – | 0.41% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 297,701 | $112,778,070 | 70.21% |
| Artia Global Partners LP | 85,204 | $32,277,831 | 12.30% |
| Avoro Capital Advisors LLC | 1,265,555 | $479,430,201 | 7.16% |
| DCF Advisers, LLC | 25,000 | $9,470,750 | 6.40% |
| Eagle Health Investments LP | 60,300 | $22,843,449 | 5.27% |
| Avidity Partners Management LP | 625,000 | $236,768,750 | 5.13% |
| Bellevue Group AG | 911,100 | $345,152,013 | 4.58% |
| Fairmount Funds Management LLC | 73,526 | $27,853,855 | 4.42% |
| Paradigm Biocapital Advisors LP | 89,556 | $33,926,499 | 3.98% |
| RTW INVESTMENTS, LP | 482,195 | $182,669,932 | 3.73% |